Adipose tissue TCF7L2 Splicing is regulated by weight loss and associates with glucose and fatty acid metabolism

Diabetes

Volumn 61, Issue 11, 2012, Pages 2807-2813

  Kaminska, Dorota ^a   Kuulasmaa, Tiina ^b   Venesmaa, Sari ^b   Käkelä, Pirjo ^b   Vaittinen, Maija ^a   Pulkkinen, Leena ^a   Pääkkönen, Matti ^b   Gylling, Helena ^a   Laakso, Markku ^b   Pihlajamäki, Jussi ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; TRANSCRIPTION FACTOR 7 LIKE 2;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HORMONE ACTION; HUMAN; HUMAN CELL; HYPERINSULINEMIA; INSULIN RELEASE; LIVER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SUBCUTANEOUS FAT; WEIGHT REDUCTION;

ABDOMINAL FAT; ADULT; ALTERNATIVE SPLICING; BIOPSY; BLOOD GLUCOSE; BODY MASS INDEX; FATTY ACIDS, NONESTERIFIED; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIVER; MALE; MIDDLE AGED; OBESITY, MORBID; RNA, MESSENGER; SUBCUTANEOUS FAT, ABDOMINAL; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN; WEIGHT LOSS;

EID: 84868035640     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0239     Document Type: Article

References (26)

1. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323
2. Gaulton KJ, Nammo T, Pasquali L, et al. A map of open chromatin in human pancreatic islets. Nat Genet 2010;42:255-259
3. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-2163
4. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009;18:2388-2399
5. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003;17:419-437
6. Mondal AK, Das SK, Baldini G, et al. Genotype and tissue-specific effects on alternative splicing of the transcription factor 7-like 2 gene in humans. J Clin Endocrinol Metab 2010;95:1450-1457
7. Osmark P, Hansson O, Jonsson A, Rönn T, Groop L, Renström E. Unique splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia 2009;52:850-854
8. Prokunina-Olsson L, Welch C, Hansson O, et al. Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet 2009;18:3795-3804
9. Le Bacquer O, Shu L, Marchand M, et al. TCF7L2 splice variants have distinct effects on beta-cell turnover and function. Hum Mol Genet 2011;20: 1906-1915
10. Weise A, Bruser K, Elfert S, et al. Alternative splicing of Tcf7l2 transcripts generates protein variants with differential promoter-binding and transcriptional activation properties at Wnt/beta-catenin targets. Nucleic Acids Res 2010;38:1964-1981
11. Pihlajamäki J, Lerin C, Itkonen P, et al. Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab 2011;14:208-218
12. Shiina H, Igawa M, Breault J, et al. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res 2003;9:2121-2132
13. Fang M, Li J, Blauwkamp T, Bhambhani C, Campbell N, Cadigan KM. C-terminal-binding protein directly activates and represses Wnt transcriptional targets in Drosophila. EMBO J 2006;25:2735-2745
14. Atcha FA, Munguia JE, Li TW, Hovanes K, Waterman ML. A new beta-catenin-dependent activation domain in T cell factor. J Biol Chem 2003; 278:16169-16175
15. Tang W, Dodge M, Gundapaneni D, Michnoff C, Roth M, Lum L. A genomewide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc Natl Acad Sci USA 2008;105:9697-9702
16. Atcha FA, Syed A, Wu B, et al. A unique DNA binding domain converts T-cell factors into strong Wnt effectors. Mol Cell Biol 2007;27:8352-8363
17. Pihlajamäki J, Kuulasmaa T, Kaminska D, et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol 2012;56:663-670
18. Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 2009;58: 1212-1221
19. Salmenniemi U, Ruotsalainen E, Pihlajamäki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004;110:3842-3848
20. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. J Clin Invest 1998;101:86-96
21. Wabitsch M, Brenner RE, Melzner I, et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord 2001;25:8-15
22. Prokunina-Olsson L, Kaplan LM, Schadt EE, Collins FS. Alternative splicing of TCF7L2 gene in omental and subcutaneous adipose tissue and risk of type 2 diabetes. PLoS ONE 2009;4:e7231
23. Patel NA, Chalfant CE, Watson JE, et al. Insulin regulates alternative splicing of protein kinase C beta II through a phosphatidylinositol 3-kinase-dependent pathway involving the nuclear serine/arginine-rich splicing factor, SRp40, in skeletal muscle cells. J Biol Chem 2001;276: 22648-22654
24. Helgason A, Pálsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007;39:218-225
25. Groves CJ, Zeggini E, Minton J, et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006;55:2640-2644
26. Florez JC, Jablonski KA, Bayley N, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355:241-250